Bionano Genomics
BNGO
About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Employees: 100
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
11% more capital invested
Capital invested by funds: $291K [Q1] → $321K (+$30.6K) [Q2]
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.67% less ownership
Funds ownership: 3.81% [Q1] → 3.15% (-0.67%) [Q2]
3% less funds holding
Funds holding: 29 [Q1] → 28 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co.
Yi Chen
|
$11
|
Buy
Maintained
|
18 Aug 2025 |
Financial journalist opinion
Based on 3 articles about BNGO published over the past 30 days